☰

Srinivasan Yegnasubramanian - Publications

Affiliations: 
Department of Oncology Johns Hopkins University School of Medicine, Baltimore, MD, United States 
Tree Info Similar researchers PubMed Report error

181 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Markowski MC, Taplin ME, Aggarwal R, Sena LA, Wang H, Qi H, Lalji A, Sinibaldi V, Carducci MA, Paller CJ, Marshall CH, Eisenberger MA, Sanin DE, Yegnasubramanian S, Gomes-Alexandre C, et al. Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial. Nature Communications. 15: 14. PMID 38167882 DOI: 10.1038/s41467-023-44514-2  0.311
2023 Lee E, Coulter J, Mishra A, Caramella-Pereira F, Demarzo A, Rudek M, Hu C, Han M, DeWeese TL, Yegnasubramanian S, Song DY. Induction of double-strand breaks with the non-steroidal androgen receptor ligand flutamide in patients on androgen suppression: a study protocol for a randomized, double-blind prospective trial. Trials. 24: 809. PMID 38104131 DOI: 10.1186/s13063-023-07838-4  0.836
2023 Chen J, Zheng Q, Hicks JL, Trabzonlu L, Ozbek B, Jones T, Vaghasia AM, Larman TC, Wang R, Markowski MC, Denmeade SR, Pienta KJ, Hruban RH, Antonarakis ES, Gupta A, ... ... Yegnasubramanian S, et al. MYC-driven increases in mitochondrial DNA copy number occur early and persist throughout prostatic cancer progression. Jci Insight. PMID 37971875 DOI: 10.1172/jci.insight.169868  0.543
2023 Mori JO, Elhussin I, Brennen WN, Graham MK, Lotan TL, Yates CC, De Marzo AM, Denmeade SR, Yegnasubramanian S, Nelson WG, Denis GV, Platz EA, Meeker AK, Heaphy CM. Prognostic and therapeutic potential of senescent stromal fibroblasts in prostate cancer. Nature Reviews. Urology. PMID 37907729 DOI: 10.1038/s41585-023-00827-x  0.868
2023 Graham MK, Wang R, Chikarmane R, Wodu B, Vaghasia A, Gupta A, Zheng Q, Hicks J, Sysa-Shah P, Pan X, Castagna N, Liu J, Meyers J, Skaist A, Zhang Y, ... ... Yegnasubramanian S, et al. Convergent alterations in the tumor microenvironment of MYC-driven human and murine prostate cancer. Biorxiv : the Preprint Server For Biology. PMID 37905029 DOI: 10.1101/2023.09.07.553268  0.867
2023 Gupta H, Inoue H, Nakai Y, Nakayama M, Jones T, Hicks JL, Kumar B, Gurel M, Nelson WG, De Marzo AM, Yegnasubramanian S. Progressive spreading of DNA methylation in the GSTP1 promoter CpG island across transitions from precursors to invasive prostate cancer. Cancer Prevention Research (Philadelphia, Pa.). PMID 37347938 DOI: 10.1158/1940-6207.CAPR-22-0485  0.527
2023 Chen J, Zheng Q, Hicks JL, Trabzonlu L, Ozbek B, Jones T, Vaghasia A, Larman TC, Wang R, Markowski MC, Denmeade SR, Pienta KJ, Hruban RH, Antonaraskis ES, Gupta A, ... ... Yegnasubramanian S, et al. MYC-driven increases in mitochondrial DNA copy number occur early and persist throughout prostatic cancer progression. Biorxiv : the Preprint Server For Biology. PMID 36865273 DOI: 10.1101/2023.02.20.529259  0.542
2023 LaVigne AW, DeWeese TL, Wright JL, Deville C, Yegnasubramanian S, Alcorn SR. Radiotherapy Deserts: Impact of Race, Poverty and the Rural-Urban Continuum on Density of Providers and Utilization of Radiotherapy in the United States. International Journal of Radiation Oncology, Biology, Physics. PMID 36736631 DOI: 10.1016/j.ijrobp.2023.01.046  0.557
2022 Graham MK, Chikarmane R, Wang R, Vaghasia A, Gupta A, Zheng Q, Wodu B, Pan X, Castagna N, Liu J, Meyers J, Skaist A, Wheelan S, Simons BW, Bieberich C, ... ... Yegnasubramanian S, et al. Single-cell atlas of epithelial and stromal cell heterogeneity by lobe and strain in the mouse prostate. The Prostate. PMID 36373171 DOI: 10.1002/pros.24460  0.827
2022 Low JY, Ko M, Hanratty B, Patel RA, Bhamidipati A, Heaphy CM, Sayar E, Lee JK, Li S, De Marzo AM, Nelson WG, Gupta A, Yegnasubramanian S, Ha G, Epstein JI, et al. Genomic Characterization of Prostatic Basal Cell Carcinoma. The American Journal of Pathology. PMID 36309102 DOI: 10.1016/j.ajpath.2022.09.010  0.625
2022 Sena LA, Kumar R, Sanin DE, Thompson EA, Rosen DM, Dalrymple SL, Antony L, Yang Y, Gomes-Alexandre C, Hicks JL, Jones T, Bowers KA, Eskra JN, Meyers J, Gupta A, ... ... Yegnasubramanian S, et al. Prostate cancer androgen receptor activity dictates efficacy of bipolar androgen therapy through MYC. The Journal of Clinical Investigation. PMID 36194476 DOI: 10.1172/JCI162396  0.529
2022 Pham MT, Gupta A, Gupta H, Vaghasia A, Skaist A, Garrison MA, Coulter JB, Haffner MC, Zheng SL, Xu J, DeStefano Shields C, Isaacs WB, Wheelan SJ, Nelson WG, Yegnasubramanian S. Identifying Phased Mutations and Complex Rearrangements in Human Prostate Cancer Cell Lines through Linked-Read Whole Genome Sequencing. Molecular Cancer Research : McR. PMID 35452513 DOI: 10.1158/1541-7786.MCR-21-0683  0.779
2022 Ozbek B, Ertunc O, Erickson A, Vidal ID, Gomes-Alexandre C, Guner G, Hicks JL, Jones T, Taube JM, Sfanos KS, Yegnasubramanian S, De Marzo AM. Multiplex immunohistochemical phenotyping of T cells in primary prostate cancer. The Prostate. PMID 35188986 DOI: 10.1002/pros.24315  0.476
2022 Nelson WG, Brawley OW, Isaacs WB, Platz EA, Yegnasubramanian S, Sfanos KS, Lotan TL, De Marzo AM. Health inequity drives disease biology to create disparities in prostate cancer outcomes. The Journal of Clinical Investigation. 132. PMID 35104804 DOI: 10.1172/JCI155031  0.667
2022 Coulter JB, Song DY, DeWeese TL, Yegnasubramanian S. Mechanisms, Challenges, and Opportunities in Combined Radiation and Hormonal Therapies. Seminars in Radiation Oncology. 32: 76-81. PMID 34861998 DOI: 10.1016/j.semradonc.2021.09.003  0.818
2021 Asrani K, Torres AFC, Woo J, Vidotto T, Tsai HK, Luo J, Corey E, Hanratty B, Coleman I, Yegnasubramanian S, De Marzo AM, Nelson PS, Haffner MC, Lotan TL. Reciprocal YAP1 loss and INSM1 expression in neuroendocrine prostate cancer. The Journal of Pathology. PMID 34431104 DOI: 10.1002/path.5781  0.53
2021 Haffner MC, Bhamidipati A, Tsai HK, Esopi DM, Vaghasia AM, Low JY, Patel RA, Guner G, Pham MT, Castagna N, Hicks J, Wyhs N, Aebersold R, De Marzo AM, Nelson WG, ... ... Yegnasubramanian S, et al. Phenotypic characterization of two novel cell line models of castration-resistant prostate cancer. The Prostate. PMID 34402095 DOI: 10.1002/pros.24210  0.636
2021 Vidal I, Zheng Q, Hicks JL, Chen J, Platz EA, Trock BJ, Kulac I, Baena-Del Valle JA, Sfanos KS, Ernst S, Jones T, Maynard JP, Glavaris SA, Nelson WG, Yegnasubramanian S, et al. GSTP1 positive prostatic adenocarcinomas are more common in Black than White men in the United States. Plos One. 16: e0241934. PMID 34191807 DOI: 10.1371/journal.pone.0241934  0.654
2021 Mishra A, Zennami K, Velarde E, Thorek DLJ, Yegnasubramanian S, DeWeese TL, Lupold SE. Longitudinal measurement of subcutaneous and intratibial human prostate cancer xenograft growth and response to ionizing radiation by plasma Alu and LINE-1 ctDNA: A comparison to standard methods. The Prostate. PMID 34032307 DOI: 10.1002/pros.24171  0.6
2021 Nizialek E, Lim SJ, Wang H, Isaacsson Velho P, Yegnasubramanian S, Antonarakis ES. Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone-sensitive prostate cancer. The Prostate. PMID 33955569 DOI: 10.1002/pros.24135  0.459
2021 Brennen WN, Zhu Y, Coleman IM, Dalrymple SL, Antony L, Patel RA, Hanratty B, Chikarmane R, Meeker AK, Zheng SL, Hooper JE, Luo J, De Marzo AM, Corey E, Xu J, ... Yegnasubramanian S, et al. Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer. Jci Insight. PMID 33724955 DOI: 10.1172/jci.insight.146827  0.74
2021 Severson TM, Zhu Y, De Marzo AM, Jones T, Simons JW, Nelson WG, Yegnasubramanian S, Freedman ML, Wessels L, Bergman AM, Haffner MC, Zwart W. Epigenetic and transcriptional analysis reveals a core transcriptional program conserved in clonal prostate cancer metastases. Molecular Oncology. PMID 33576154 DOI: 10.1002/1878-0261.12923  0.688
2020 Haffner MC, Zwart W, Roudier MP, True LD, Nelson WG, Epstein JI, De Marzo AM, Nelson PS, Yegnasubramanian S. Genomic and phenotypic heterogeneity in prostate cancer. Nature Reviews. Urology. PMID 33328650 DOI: 10.1038/s41585-020-00400-w  0.684
2020 Wise DR, Schneider JA, Armenia J, Febles VA, McLaughlin B, Brennan R, Thoren KL, Abida W, Sfanos KS, De Marzo AM, Yegnasubramanian S, Fox JJ, Haas M, Heath H, Kagey MH, et al. Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate Cancer. Jco Precision Oncology. 4. PMID 33015525 DOI: 10.1200/PO.20.00097  0.533
2020 Esopi D, Graham MK, Brosnan-Cashman JA, Meyers J, Vaghasia A, Gupta A, Kumar B, Haffner MC, Heaphy CM, De Marzo AM, Meeker AK, Nelson WG, Wheelan SJ, Yegnasubramanian S. Pervasive promoter hypermethylation of silenced TERT alleles in human cancers. Cellular Oncology (Dordrecht). PMID 32468444 DOI: 10.1007/S13402-020-00531-7  0.813
2020 Freeman ZT, Nirschl TR, Hovelson DH, Johnston RJ, Engelhardt JJ, Selby MJ, Kochel CM, Lan RY, Zhai J, Ghasemzadeh A, Gupta A, Skaist AM, Wheelan SJ, Jiang H, Pearson AT, ... ... Yegnasubramanian S, et al. A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target. The Journal of Clinical Investigation. PMID 32015231 DOI: 10.1172/Jci128672  0.352
2020 Marshall CH, Yegnasubramanian S, Wang H, Durham J, Wang T, Damico R, D'Alessio FR, Sidhaye VK, Pekosz A, Mankowski JL, Klein SL, Murli S, Jaffee EM, Denmeade SR. Abstract IA09: A phase II trial to promote recovery from COVID-19 with endocrine therapy Clinical Cancer Research. 26. DOI: 10.1158/1557-3265.Covid-19-Ia09  0.403
2020 Sidiropoulos DN, Davis-Marcisak E, Rafie C, Kagohara LT, Sharma G, Connolly RM, Stearns V, Yegnasubramanian S, Jaffee EM, Fertig EJ, Torres ETR. Abstract 1555: Single cell level treatment-specific characterization of HER2+ breast cancers treated with immune checkpoint inhibitors and entinostat Tumor Biology. DOI: 10.1158/1538-7445.Am2020-1555  0.34
2019 Mao W, Ghasemzadeh A, Freeman ZT, Obradovic A, Chaimowitz MG, Nirschl TR, McKiernan E, Yegnasubramanian S, Drake CG. Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition. Journal For Immunotherapy of Cancer. 7: 277. PMID 31653272 DOI: 10.1186/S40425-019-0758-Y  0.615
2019 Porter CM, Haffner MC, Kulac I, Maynard JP, Baena-Del Valle JA, Isaacs WB, Yegnasubramanian S, De Marzo AM, Sfanos KS. Lactoferrin CpG Island Hypermethylation and Decoupling of mRNA and Protein Expression in the Early Stages of Prostate Carcinogenesis. The American Journal of Pathology. PMID 31499027 DOI: 10.1016/J.Ajpath.2019.07.016  0.619
2019 Ando M, Saito Y, Xu G, Bui NQ, Medetgul-Ernar K, Pu M, Fisch K, Ren S, Sakai A, Fukusumi T, Liu C, Haft S, Pang J, Mark A, Gaykalova DA, ... ... Yegnasubramanian S, et al. Publisher Correction: Chromatin dysregulation and DNA methylation at transcription start sites associated with transcriptional repression in cancers. Nature Communications. 10: 2415. PMID 31142745 DOI: 10.1038/S41467-019-10557-7  0.332
2019 Giovinazzo H, Walker D, Wyhs N, Liu J, Esopi DM, Vaghasia AM, Jain Y, Bhamidipati A, Zhou J, Nelson WG, Yegnasubramanian S. A high-throughput screen of pharmacologically active compounds for inhibitors of UHRF1 reveals epigenetic activity of anthracycline derivative chemotherapeutic drugs. Oncotarget. 10: 3040-3050. PMID 31105884 DOI: 10.18632/Oncotarget.26889  0.554
2019 Ando M, Saito Y, Xu G, Bui NQ, Medetgul-Ernar K, Pu M, Fisch K, Ren S, Sakai A, Fukusumi T, Liu C, Haft S, Pang J, Mark A, Gaykalova DA, ... ... Yegnasubramanian S, et al. Chromatin dysregulation and DNA methylation at transcription start sites associated with transcriptional repression in cancers. Nature Communications. 10: 2188. PMID 31097695 DOI: 10.1038/S41467-019-09937-W  0.391
2019 Kong X, Chen J, Xie W, Brown SM, Cai Y, Wu K, Fan D, Nie Y, Yegnasubramanian S, Tiedemann RL, Tao Y, Chiu Yen RW, Topper MJ, Zahnow CA, Easwaran H, et al. Defining UHRF1 Domains that Support Maintenance of Human Colon Cancer DNA Methylation and Oncogenic Properties. Cancer Cell. PMID 30956060 DOI: 10.1016/J.Ccell.2019.03.003  0.409
2019 Ashok A, Keener RA, Rubenstein M, Stookey S, Bajpai S, Hicks J, Alme AK, Drake CG, Zheng Q, Trabzonlu L, Yegnasubramanian S, De Marzo AM, Bieberich CJ. Consequences of interleukin 1β-triggered chronic inflammation in the mouse prostate gland: Altered architecture associated with prolonged CD4 infiltration mimics human proliferative inflammatory atrophy. The Prostate. PMID 30900284 DOI: 10.1002/Pros.23784  0.517
2019 Sfanos KS, Yegnasubramanian S, Nelson WG, Lotan TL, Kulac I, Hicks JL, Zheng Q, Bieberich CJ, Haffner MC, De Marzo AM. If this is true, what does it imply? How end-user antibody validation facilitates insights into biology and disease. Asian Journal of Urology. 6: 10-25. PMID 30775245 DOI: 10.1016/J.Ajur.2018.11.006  0.454
2019 Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, Sonpavde G, Sternberg CN, Yegnasubramanian S, Antonarakis ES. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. European Urology. 75: 88-99. PMID 29673712 DOI: 10.1016/J.Eururo.2018.03.028  0.604
2019 Caushi JX, Ji Z, Zhang J, Asmar ME, Anagnostou V, Cottrell TR, Chan HY, Guo H, Merghoub T, Wolchok JD, Naidoo J, Marrone KA, Chaft JE, Hellmann MD, Gabrielson E, ... ... Yegnasubramanian S, et al. Abstract 4041: Coupling neoantigen specific T cell clonotypes and their molecular phenotypes at the single cell level in resectable anti-PD-1 treated NSCLC Cancer Research. 79: 4041-4041. DOI: 10.1158/1538-7445.Am2019-4041  0.346
2019 Mishra A, Zennami K, Velarde E, Coulter JB, Yegnasubramanian S, Lupold S, DeWeese TL. Circulating Tumor DNA Is an Accurate Measurement of Determining Radiation-Induced Therapeutic Response and Tumor Burden Monitoring in a Prostate Cancer Bone Metastases Murine Model International Journal of Radiation Oncology Biology Physics. 105. DOI: 10.1016/J.Ijrobp.2019.06.1065  0.802
2018 Mottahedeh J, Haffner MC, Grogan TR, Hashimoto T, Crowell PD, Beltran H, Sboner A, Bareja R, Esopi D, Isaacs WB, Yegnasubramanian S, Rettig MB, Elashoff DA, Platz EA, De Marzo AM, et al. CD38 is methylated in prostate cancer and regulates extracellular NAD. Cancer & Metabolism. 6: 13. PMID 30258629 DOI: 10.1186/S40170-018-0186-3  0.574
2018 Haffner MC, Taheri D, Luidy-Imada E, Palsgrove DN, Eich ML, Netto GJ, Matoso A, Nirschl TR, Zheng Q, Hicks JL, Nelson WG, De Marzo AM, Marchionni L, Drake CG, Yegnasubramanian S. Hypomethylation, endogenous retrovirus expression, and interferon signaling in testicular germ cell tumors. Proceedings of the National Academy of Sciences of the United States of America. PMID 30181298 DOI: 10.1073/Pnas.1803292115  0.533
2018 Trabzonlu L, Kulac I, Zheng Q, Hicks JL, Haffner MC, Nelson WG, Sfanos KS, Ertunc O, Lotan TL, Heaphy CM, Meeker AK, Yegnasubramanian S, De Marzo AM. Molecular Pathology of High-Grade Prostatic Intraepithelial Neoplasia: Challenges and Opportunities. Cold Spring Harbor Perspectives in Medicine. PMID 30082453 DOI: 10.1101/Cshperspect.A030403  0.761
2018 Yegnasubramanian S, De Marzo AM, Nelson WG. Prostate Cancer Epigenetics: From Basic Mechanisms to Clinical Implications. Cold Spring Harbor Perspectives in Medicine. PMID 29959132 DOI: 10.1101/Cshperspect.A030445  0.74
2018 Markowski MC, Hubbard GK, Hicks JL, Zheng Q, King A, Esopi D, Rege A, Yegnasubramanian S, Bieberich CJ, De Marzo AM. Characterization of novel cell lines derived from a MYC-driven murine model of lethal metastatic adenocarcinoma of the prostate. The Prostate. PMID 29851094 DOI: 10.1002/Pros.23657  0.626
2018 Torres A, Alshalalfa M, Davicioni E, Gupta A, Yegnasubramanian S, Wheelan SJ, Epstein JI, De Marzo AM, Lotan TL. ETS2 is a prostate basal cell marker and is highly expressed in prostate cancers aberrantly expressing p63. The Prostate. PMID 29761525 DOI: 10.1002/Pros.23646  0.556
2018 Nelson WG, Haffner MC, Yegnasubramanian S. The structure of the nucleus in normal and neoplastic prostate cells: untangling the role of type 2 DNA topoisomerases. American Journal of Clinical and Experimental Urology. 6: 107-113. PMID 29666839  0.627
2018 Haffner MC, Guner G, Taheri D, Netto GJ, Palsgrove DN, Zheng Q, Guedes LB, Kim K, Tsai H, Esopi DM, Lotan T, Sharma R, Meeker AK, Chinnaiyan AM, Nelson WG, ... Yegnasubramanian S, et al. Comprehensive evaluation of PD-L1 expression in primary and metastatic prostate cancer. The American Journal of Pathology. PMID 29577933 DOI: 10.1016/J.Ajpath.2018.02.014  0.688
2018 Giovinazzo H, Reichert ZR, Bergman A, Lin X, Wyhs N, Esopi D, Vaghasia A, Liu J, Jain Y, Bhamidipati A, Steinberg R, Speed T, Vaughn M, Zhang Y, Brennen N, ... ... Yegnasubramanian S, et al. Abstract 5881: Novel inhibitors of the epigenetic reader protein MBD2 Cancer Research. 78: 5881-5881. DOI: 10.1158/1538-7445.Am2018-5881  0.684
2018 Huang W, Purdue MP, Su LJ, Katki HA, Moore LE, Yegnasubramanian S, Berndt SI. Abstract 3231: Prospective study of genomic 5-methylcytosine and LINE-1 methylation levels of leukocyte DNA and colorectal cancer risk Epidemiology. DOI: 10.1158/1538-7445.Am2018-3231  0.399
2018 Coulter JB, Haffner MC, Mian OY, Hedayati M, Zhang Y, Zhou H, Mishra A, Nelson W, Song D, Yegnasubramanian S, DeWeese TL. Hydroxyflutamide Induces Androgen Receptor-Mediated DNA Damage and Radiosensitizes Prostate Cancer Cells While Preventing Induction of Pro-Growth Programs International Journal of Radiation Oncology Biology Physics. 102. DOI: 10.1016/J.Ijrobp.2018.07.667  0.844
2017 Sfanos KS, Yegnasubramanian S, Nelson WG, De Marzo AM. The inflammatory microenvironment and microbiome in prostate cancer development. Nature Reviews. Urology. PMID 29089606 DOI: 10.1038/Nrurol.2017.167  0.711
2017 Baena-Del Valle JA, Zheng Q, Esopi DM, Rubenstein M, Hubbard GK, Moncaliano MC, Hruszkewycz A, Vaghasia A, Yegnasubramanian S, Wheelan SJ, Meeker AK, Heaphy CM, Graham MK, De Marzo AM. MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer. The Journal of Pathology. PMID 28888037 DOI: 10.1002/Path.4980  0.866
2017 Shrestha E, White JR, Yu SH, Kulac I, Ertunc O, De Marzo AM, Yegnasubramanian S, Mangold LA, Partin AW, Sfanos KS. Profiling the Urinary Microbiome in Men with Positive versus Negative Biopsies for Prostate Cancer. The Journal of Urology. PMID 28797714 DOI: 10.1016/J.Juro.2017.08.001  0.619
2017 Haffner MC, Esopi DM, Chaux A, Gürel M, Ghosh S, Vaghasia AM, Tsai H, Kim K, Castagna N, Lam H, Hicks J, Wyhs N, Biswal Shinohara D, Hurley PJ, Simons BW, ... ... Yegnasubramanian S, et al. AIM1 is an actin-binding protein that suppresses cell migration and micrometastatic dissemination. Nature Communications. 8: 142. PMID 28747635 DOI: 10.1038/S41467-017-00084-8  0.685
2017 Guo T, Sakai A, Afsari B, Considine M, Danilova L, Favorov AV, Yegnasubramanian S, Kelley DZ, Flam E, Ha PK, Khan Z, Wheelan SJ, Gutkind JS, Fertig EJ, Gaykalova DA, et al. A novel functional splice variant of AKT3 defined by analysis of alternative splice expression in HPV-positive oropharyngeal cancers. Cancer Research. PMID 28733453 DOI: 10.1158/0008-5472.Can-16-3106  0.352
2017 Mattox AK, Wang Y, Springer S, Cohen JD, Yegnasubramanian S, Nelson WG, Kinzler KW, Vogelstein B, Papadopoulos N. Bisulfite-converted duplexes for the strand-specific detection and quantification of rare mutations. Proceedings of the National Academy of Sciences of the United States of America. PMID 28416672 DOI: 10.1073/Pnas.1701382114  0.457
2017 Barfeld SJ, Urbanucci A, Itkonen HM, Fazli L, Hicks JL, Thiede B, Rennie PS, Yegnasubramanian S, DeMarzo AM, Mills IG. c-Myc Antagonises the Transcriptional Activity of the Androgen Receptor in Prostate Cancer Affecting Key Gene Networks. Ebiomedicine. PMID 28412251 DOI: 10.1016/J.Ebiom.2017.04.006  0.494
2017 Ajiboye AS, Esopi D, Yegnasubramanian S, Denmeade SR. Androgen Receptor Splice Variants Are Not Substrates of Nonsense-Mediated Decay. The Prostate. PMID 28224650 DOI: 10.1002/Pros.23323  0.399
2017 Ferrari AC, Chen Y, Sabaawy HE, Stein MN, Foran D, Yegnasubramanian ST. Genome-wide alterations in gene expression of prostate cancer (PC) cells surviving neoadjuvant androgen deprivation therapy (ADT). Journal of Clinical Oncology. 35: 88-88. DOI: 10.1200/Jco.2017.35.6_Suppl.88  0.365
2017 Ferrari AC, Sabaawy H, Stein M, Foran D, Chen Y, Yegnasubramanian S. Abstract 2415: Genome-wide alterations in gene expression of prostate cancer (PC) cells surviving neo-adjuvant androgen deprivation therapy Cancer Research. 77: 2415-2415. DOI: 10.1158/1538-7445.Am2017-2415  0.576
2016 Puhr M, De Marzo A, Isaacs W, Lucia MS, Sfanos K, Yegnasubramanian S, Culig Z. Inflammation, Microbiota, and Prostate Cancer. European Urology Focus. 2: 374-382. PMID 28723469 DOI: 10.1016/J.Euf.2016.08.010  0.594
2016 Coulter JB, Haffner MC, Mian OY, Kim K, Hedayati M, Zhang Y, Zhou H, Nelson W, Yegnasubramanian S, DeWeese TL. Partial Agonist Activity of Hydroxyflutamide Induces AR- and TOP2B-dependent DNA Double Strand Breaks and Radiosensitizes Prostate Cancer Cells. International Journal of Radiation Oncology, Biology, Physics. 96: S19. PMID 27675748 DOI: 10.1016/J.Ijrobp.2016.06.059  0.855
2016 Yegnasubramanian S. Prostate cancer epigenetics and its clinical implications. Asian Journal of Andrology. 18: 549-58. PMID 27212125 DOI: 10.4103/1008-682X.179859  0.622
2016 Anders NM, Liu J, Wanjiku T, Giovinazzo H, Zhou J, Vaghasia A, Nelson WG, Yegnasubramanian S, Rudek MA. Simultaneous quantitative determination of 5-aza-2'-deoxycytidine genomic incorporation and DNA demethylation by liquid chromatography tandem mass spectrometry as exposure-response measures of nucleoside analog DNA methyltransferase inhibitors. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1022: 38-45. PMID 27082761 DOI: 10.1016/J.Jchromb.2016.03.029  0.494
2016 Hedayati M, Haffner MC, Coulter J, Raval RR, Zhang Y, Zhou H, Mian O, Knight EJ, Dalrymple S, Isaacs JT, Santos A, Hales RK, Razavi N, Nelson WG, Yegnasubramanian S, et al. Androgen deprivation followed by acute androgen stimulation selectively sensitizes AR-positive prostate cancer cells to ionizing radiation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26831716 DOI: 10.1158/1078-0432.Ccr-15-1147  0.847
2016 De Marzo AM, Haffner MC, Lotan TL, Yegnasubramanian S, Nelson WG. Premalignancy in Prostate Cancer: Rethinking What we Know. Cancer Prevention Research (Philadelphia, Pa.). PMID 26813971 DOI: 10.1158/1940-6207.Capr-15-0431  0.608
2016 Munari E, Chaux A, Vaghasia AM, Taheri D, Karram S, Bezerra SM, Gonzalez Roibon N, Nelson WG, Yegnasubramanian S, Netto GJ, Haffner MC. Global 5-Hydroxymethylcytosine Levels Are Profoundly Reduced in Multiple Genitourinary Malignancies. Plos One. 11: e0146302. PMID 26785262 DOI: 10.1371/Journal.Pone.0146302  0.491
2016 Haffner MC, Netto GJ, Nelson WG, Yegnasubramanian S, Lecksell KL, Cubilla AL, Chaux A. 5-hydroxy-methyl-cytosine content is strongly associated with degree of histological differentiation in penile squamous cell carcinomas F1000research. 5. DOI: 10.7490/F1000Research.1113197.1  0.454
2016 Haffner MC, Chaux A, Meeker AK, Esopi DM, Gerber J, Pellakuru LG, Toubaji A, Argani P, Iacobuzio-Donahue C, Nelson WG, Netto GJ, Marzo AMD, Yegnasubramanian S. Global 5-hydroxymethylcytosine content is significantly reduced in human cancers F1000research. 5. DOI: 10.7490/F1000Research.1113177.1  0.678
2016 Haffner MC, Yegnasubramanian S, Netto GJ, Chaux A. Immunohistochemical expression of AIM1 in normal prostate and in primary and metastatic prostate carcinoma F1000research. 5. DOI: 10.7490/F1000Research.1113169.1  0.558
2016 Clarke MA, Esopi D, Yegnasubramanian S, Platz EA, Joshu CE. Abstract LB-379: A targeted, next-generation bisulfite sequencing approach to evaluate the influence of maternal pre-pregnancy body mass index and gestational weight gain on umbilical cord blood DNA methylation levels Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-379  0.318
2016 Valle JABD, Zheng Q, Rubenstein M, Meeker AK, Heaphy CM, Hubbard G, Bieberich CJ, Yegnasubramanian S, Esopi D, Wheelan SJ, Marzo AMD. Abstract LB-160: Human telomerase RNA component (hTR/TERC) is consistently overexpressed in prostate cancer, required for cell proliferation and is positively regulated by MYC Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-160  0.745
2015 Hubbard GK, Mutton LN, Khalili M, McMullin RP, Hicks JL, Bianchi-Frias D, Horn LA, Kulac I, Moubarek MS, Nelson PS, Yegnasubramanian S, De Marzo AM, Bieberich CJ. Combined MYC activation and Pten loss are sufficient to create genomic instability and lethal metastatic prostate cancer. Cancer Research. PMID 26554830 DOI: 10.1158/0008-5472.Can-14-3280  0.637
2015 Mian OY, Khattab MH, Hedayati M, Coulter J, Abubaker-Sharif B, Schwaninger JM, Veeraswamy RK, Brooks JD, Hopkins L, Shinohara DB, Cornblatt B, Nelson WG, Yegnasubramanian S, DeWeese TL. GSTP1 Loss results in accumulation of oxidative DNA base damage and promotes prostate cancer cell survival following exposure to protracted oxidative stress. The Prostate. PMID 26447830 DOI: 10.1002/Pros.23111  0.843
2015 Haffner MC, Weier C, Xu M, Vaghasia A, Gürel B, Gümüşkaya B, Esopi DM, Fedor H, Tan HL, Kulac I, Hicks J, Isaacs WB, Lotan TL, Nelson WG, Yegnasubramanian S, et al. Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization. The Journal of Pathology. PMID 26331372 DOI: 10.1002/Path.4628  0.645
2015 Hurley PJ, Hughes RM, Simons B, Huang J, Miller RM, Shinder B, Haffner MC, Esopi D, Kinura Y, Jabbari J, Ross AE, Erho N, Vergara IA, Faraj SF, Davicioni E, ... ... Yegnasubramanian S, et al. Androgen Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression. Cancer Research. PMID 26294211 DOI: 10.1158/0008-5472.Can-15-0024  0.64
2015 Kulac I, Haffner MC, Yegnasubramanian S, Epstein JI, De Marzo AM. Should Gleason 6 be labeled as cancer? Current Opinion in Urology. 25: 238-45. PMID 25730327 DOI: 10.1097/Mou.0000000000000165  0.565
2015 Schweizer MT, Antonarakis ES, Wang H, Ajiboye AS, Spitz A, Cao H, Luo J, Haffner MC, Yegnasubramanian S, Carducci MA, Eisenberger MA, Isaacs JT, Denmeade SR. Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study. Science Translational Medicine. 7: 269ra2. PMID 25568070 DOI: 10.1126/Scitranslmed.3010563  0.548
2015 Tan HL, Haffner MC, Esopi DM, Vaghasia AM, Giannico GA, Ross HM, Ghosh S, Hicks JL, Zheng Q, Sangoi AR, Yegnasubramanian S, Osunkoya AO, De Marzo AM, Epstein JI, Lotan TL. Prostate adenocarcinomas aberrantly expressing p63 are molecularly distinct from usual-type prostatic adenocarcinomas. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 28: 446-56. PMID 25216229 DOI: 10.1038/Modpathol.2014.115  0.537
2015 Haffner MC, De Marzo AM, Yegnasubramanian S, Epstein JI, Carter HB. Diagnostic challenges of clonal heterogeneity in prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: e38-40. PMID 24638011 DOI: 10.1200/Jco.2013.50.3540  0.633
2015 Hubbard GK, Yu S, Shinohara DB, Vaghasia A, Nelson WG, Yegnasubramanian S, Marzo AMD, Sfanos KS. Abstract 5021: Histopathologic and gene expression analysis in mouse models of long-term chronic prostatic inflammation using human prostate cancer-derived bacterial isolates Immunology. 75: 5021-5021. DOI: 10.1158/1538-7445.Am2015-5021  0.683
2015 Kulac I, Haffner MC, Yegnasubramanian S, Epstein JI, De Marzo AM. Should Gleason 6 be labeled as cancer? Current Opinion in Urology. 25: 238-245. DOI: 10.1097/MOU.0000000000000165  0.325
2015 Coulter J, Haffner M, Mian O, Hedayati M, Zhang Y, Zhou H, Nelson W, Yegnasubramanian S, DeWeese T. Generation of DNA Double Strand Breaks in Prostate Cancer Cells by Androgen Receptor Antagonists, Hydroxyflutamide and Bicalutamide International Journal of Radiation Oncology*Biology*Physics. 93: S185. DOI: 10.1016/J.Ijrobp.2015.07.443  0.853
2015 Mian O, Haffner M, Coulter J, Esopi D, Meyers J, Gergis C, Assadi R, Nelson W, Yegnasubramanian S, DeWeese T. A Novel Technology for Noninvasive Detection of Prostate Cancer DNA in the Blood and Urine of Men With High-Risk PCA Receiving Radiation Therapy and Androgen Suppression International Journal of Radiation Oncology*Biology*Physics. 93: E226. DOI: 10.1016/J.Ijrobp.2015.07.1117  0.839
2014 Khor TO, Fuentes F, Shu L, Paredes-Gonzalez X, Yang AY, Liu Y, Smiraglia DJ, Yegnasubramanian S, Nelson WG, Kong AN. Epigenetic DNA methylation of antioxidative stress regulator NRF2 in human prostate cancer. Cancer Prevention Research (Philadelphia, Pa.). 7: 1186-97. PMID 25266896 DOI: 10.1158/1940-6207.Capr-14-0127  0.738
2014 Lin MT, Mosier SL, Thiess M, Beierl KF, Debeljak M, Tseng LH, Chen G, Yegnasubramanian S, Ho H, Cope L, Wheelan SJ, Gocke CD, Eshleman JR. Clinical validation of KRAS, BRAF, and EGFR mutation detection using next-generation sequencing. American Journal of Clinical Pathology. 141: 856-66. PMID 24838331 DOI: 10.1309/Ajcpmwgwgo34Egod  0.32
2014 Guerrero-Preston R, Michailidi C, Marchionni L, Pickering CR, Frederick MJ, Myers JN, Yegnasubramanian S, Hadar T, Noordhuis MG, Zizkova V, Fertig E, Agrawal N, Westra W, Koch W, Califano J, et al. Key tumor suppressor genes inactivated by "greater promoter" methylation and somatic mutations in head and neck cancer. Epigenetics : Official Journal of the Dna Methylation Society. 9: 1031-46. PMID 24786473 DOI: 10.4161/Epi.29025  0.347
2014 Sharad S, Ravindranath L, Haffner MC, Li H, Yan W, Sesterhenn IA, Chen Y, Ali A, Srinivasan A, McLeod DG, Yegnasubramanian S, Srivastava S, Dobi A, Petrovics G. Methylation of the PMEPA1 gene, a negative regulator of the androgen receptor in prostate cancer. Epigenetics : Official Journal of the Dna Methylation Society. 9: 918-27. PMID 24694733 DOI: 10.4161/Epi.28710  0.608
2014 Wyhs N, Walker D, Giovinazzo H, Yegnasubramanian S, Nelson WG. Time-Resolved Fluorescence Resonance Energy Transfer Assay for Discovery of Small-Molecule Inhibitors of Methyl-CpG Binding Domain Protein 2. Journal of Biomolecular Screening. 19: 1060-1069. PMID 24608100 DOI: 10.1177/1087057114526433  0.47
2014 Darshan M, Zheng Q, Fedor HL, Wyhs N, Yegnasubramanian S, Lee P, Melamed J, Netto GJ, Trock BJ, De Marzo AM, Sfanos KS. Biobanking of derivatives from radical retropubic and robot-assisted laparoscopic prostatectomy tissues as part of the prostate cancer biorepository network. The Prostate. 74: 61-9. PMID 24115205 DOI: 10.1002/Pros.22730  0.618
2014 Nelson WG, Demarzo AM, Yegnasubramanian S. The diet as a cause of human prostate cancer. Cancer Treatment and Research. 159: 51-68. PMID 24114474 DOI: 10.1007/978-3-642-38007-5_4  0.724
2014 Canene-Adams K, Sfanos KS, Liang CT, Yegnasubramanian S, Nelson WG, Brayton C, De Marzo AM. Correction: Dietary chemoprevention of PhIP induced carcinogenesis in male fischer 344 rats with tomato and broccoli (PLoS ONE) Plos One. 9. DOI: 10.1371/annotation/3fd9703c-a6d9-4715-9c93-cf5279ea4fa6  0.328
2014 Canene-Adams K, Sfanos KS, Liang CT, Yegnasubramanian S, Nelson WG, Brayton C, De Marzo AM. Dietary chemoprevention of PhIP induced carcinogenesis in male fischer 344 rats with tomato and broccoli (PLOS ONE) Plos One. 9. DOI: 10.1371/annotation/1ac6412e-619f-4575-8b63-f5e16bd3252b  0.329
2014 Wyhs NA, Giovinazzo H, Walker D, Yegnasubramanian S, Nelson WG. Abstract LB-129: Small molecular library screening to find methyl binding domain 2 protein inhibitors Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-129  0.542
2014 Li H, Sharad S, Ravindranath L, Haffner M, Heidenberg D, Yegnasubramanian S, Chen Y, Mohamed A, Srinivasan A, Petrovics G, Srivastava S. Abstract 5566: Functional new insights into the regulation of the androgen receptor by PMEPA1/NEDD4-1 in prostate cancer Cancer Research. 74: 5566-5566. DOI: 10.1158/1538-7445.Am2014-5566  0.636
2014 Walker DA, Wyhs N, Giovinazzo H, Yegnasubramanian S, Nelson WG. Abstract 5390: Development of a high-throughput screening assay to identify UHRF1 inhibitors via time-resolved fluorescence resonance energy transfer (TR-FRET) Cancer Research. 74: 5390-5390. DOI: 10.1158/1538-7445.Am2014-5390  0.522
2014 Guerrero-Preston R, Michailidi C, Marchionni L, Pickering C, Frederick M, Myers J, Yegnasubramanian S, Hadar T, Noordhuis M, Fertig E, Agrawal N, Westra W, Koch W, Califano J, Velculescu V, et al. Abstract 2482: Key tumor suppressor genes inactivated by promoter methylation and somatic mutations in head and neck cancer Cancer Research. 74: 2482-2482. DOI: 10.1158/1538-7445.Am2014-2482  0.378
2014 Sharad S, Li H, Ravindranath L, Haffner M, Heidenberg D, Yegnasubramanian S, Chen Y, Mohamed A, Srinivasan A, Petrovics G, Dobi A, Srivastava S. Mp24-03 Methylation Of The Pmepa1 Gene Disrupts The Control Of Androgen Receptor In Prostate Cancer The Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.284  0.597
2013 Bardia A, Blackford AL, Lin J, Armstrong AJ, King S, Rudek MA, Yegnasubramanian ST, Carducci MA. A prostate cancer clinical trials consortium trial of disulfiram (D) in men with nonmetastatic recurrent prostate cancer (PCa). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 219. PMID 28137035 DOI: 10.1200/Jco.2013.31.6_Suppl.219  0.522
2013 Canene-Adams K, Sfanos KS, Liang CT, Yegnasubramanian S, Nelson WG, Brayton C, De Marzo AM. Dietary chemoprevention of PhIP induced carcinogenesis in male Fischer 344 rats with tomato and broccoli. Plos One. 8: e79842. PMID 24312188 DOI: 10.1371/Journal.Pone.0079842  0.552
2013 Haffner MC, Mosbruger T, Esopi DM, Fedor H, Heaphy CM, Walker DA, Adejola N, Gürel M, Hicks J, Meeker AK, Halushka MK, Simons JW, Isaacs WB, De Marzo AM, Nelson WG, ... Yegnasubramanian S, et al. Tracking the clonal origin of lethal prostate cancer. The Journal of Clinical Investigation. 123: 4918-22. PMID 24135135 DOI: 10.1172/Jci70354  0.79
2013 Nelson WG, Yegnasubramanian S. Resistance emerges to second-generation antiandrogens in prostate cancer. Cancer Discovery. 3: 971-4. PMID 24019330 DOI: 10.1158/2159-8290.Cd-13-0405  0.678
2013 Schweizer MT, Lin J, Blackford A, Bardia A, King S, Armstrong AJ, Rudek MA, Yegnasubramanian S, Carducci MA. Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer. Prostate Cancer and Prostatic Diseases. 16: 357-61. PMID 23958896 DOI: 10.1038/Pcan.2013.28  0.623
2013 Haffner MC, Pellakuru LG, Ghosh S, Lotan TL, Nelson WG, De Marzo AM, Yegnasubramanian S. Tight correlation of 5-hydroxymethylcytosine and Polycomb marks in health and disease. Cell Cycle (Georgetown, Tex.). 12: 1835-41. PMID 23676216 DOI: 10.4161/Cc.25010  0.59
2013 Gerber JM, Gucwa JL, Esopi D, Gurel M, Haffner MC, Vala M, Nelson WG, Jones RJ, Yegnasubramanian S. Genome-wide comparison of the transcriptomes of highly enriched normal and chronic myeloid leukemia stem and progenitor cell populations. Oncotarget. 4: 715-28. PMID 23651669 DOI: 10.18632/Oncotarget.990  0.489
2013 Yegnasubramanian S, Maitra A. Aiming for the outliers: cancer precision medicine through targeting kinases with extreme expression. Cancer Discovery. 3: 252-4. PMID 23475875 DOI: 10.1158/2159-8290.Cd-13-0016  0.329
2013 Weier C, Haffner MC, Mosbruger T, Esopi DM, Hicks J, Zheng Q, Fedor H, Isaacs WB, De Marzo AM, Nelson WG, Yegnasubramanian S. Nucleotide resolution analysis of TMPRSS2 and ERG rearrangements in prostate cancer. The Journal of Pathology. 230: 174-83. PMID 23447416 DOI: 10.1002/Path.4186  0.662
2013 Shinohara DB, Vaghasia AM, Yu SH, Mak TN, Brüggemann H, Nelson WG, De Marzo AM, Yegnasubramanian S, Sfanos KS. A mouse model of chronic prostatic inflammation using a human prostate cancer-derived isolate of Propionibacterium acnes. The Prostate. 73: 1007-15. PMID 23389852 DOI: 10.1002/Pros.22648  0.696
2013 Aryee MJ, Liu W, Engelmann JC, Nuhn P, Gurel M, Haffner MC, Esopi D, Irizarry RA, Getzenberg RH, Nelson WG, Luo J, Xu J, Isaacs WB, Bova GS, Yegnasubramanian S. DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Science Translational Medicine. 5: 169ra10. PMID 23345608 DOI: 10.1126/Scitranslmed.3005211  0.635
2013 Sharad SE, Li H, Haffner M, Yegnasubramanian S, Ravindranth L, Chen Y, Srinivasan A, Petrovics G, Srivastava S, Dobi A. Abstract 4245: Silencing of the PMEPA1 gene, a key regulator of androgen receptor in prostate cancer. Cancer Research. 73: 4245-4245. DOI: 10.1158/1538-7445.Am2013-4245  0.603
2013 Shinohara DB, Vaghasia A, Yu S, Nelson WG, Marzo AMD, Yegnasubramanian S, Sfanos KS. Abstract 312: A mouse model of chronic prostatic inflammation using a human prostate cancer-derived isolate of Propionibacterium acnes. Cancer Research. 73: 312-312. DOI: 10.1158/1538-7445.Am2013-312  0.699
2013 Kwabi-Addo B, Wang S, Furbert-Harris P, Yegnasubramanian S, Devaney J. Abstract 1974: Functional characterization of Basonuclin 1 (BNC1): a novel tumor suppressor gene commonly downregulated in human prostate cancer. Cancer Research. 73: 1974-1974. DOI: 10.1158/1538-7445.Am2013-1974  0.639
2013 Weier C, Haffner M, Mosbruger T, Esopi D, Hicks J, Zheng Q, Isaacs WB, Marzo AMD, Nelson WG, Yegnasubramanian S. Abstract 1773: Nucleotide-resolution genomic breakpoint analysis of TMPRSS2-ERG rearrangements in prostate cancer by target-capture next-generation sequencing. Cancer Research. 73: 1773-1773. DOI: 10.1158/1538-7445.Am2013-1773  0.664
2013 Hubbard GK, Mutton LN, Khalili M, McMullin RP, Hicks J, Bianchi-Frias D, Nelson PS, Yegnasubramanian S, Marzo AMD, Bieberich CJ. Abstract 1086: MYC overexpression combined with Pten loss generates genomic instability and rapid metastasis in a new mouse model of lethal prostate adenocarcinoma. Cancer Research. 73: 1086-1086. DOI: 10.1158/1538-7445.Am2013-1086  0.552
2013 Uemura M, Yegnasubramanian S, Nelson W, Nonomura N, De Marzo A. 943 Epigenetic and transcriptional mechanisms by which MYC regulates rRNA levels European Urology Supplements. 12: e943-e944. DOI: 10.1016/S1569-9056(13)61422-0  0.376
2013 Sharad S, Li H, Haffner M, Yegnasubramanian S, Ravindranath L, Chen Y, Srinivasan A, Petrovics G, Srivastava S, Dobi A. 987 Silencing Of The Pmepa1 Gene, A Key Regulator Of Androgen Receptor In Prostate Cancer The Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.569  0.605
2012 Huang WY, Su LJ, Hayes RB, Moore LE, Katki HA, Berndt SI, Weissfeld JL, Yegnasubramanian S, Purdue MP. Prospective study of genomic hypomethylation of leukocyte DNA and colorectal cancer risk. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 21: 2014-21. PMID 23001241 DOI: 10.1158/1055-9965.Epi-12-0700-T  0.406
2012 Orr BA, Haffner MC, Nelson WG, Yegnasubramanian S, Eberhart CG. Decreased 5-hydroxymethylcytosine is associated with neural progenitor phenotype in normal brain and shorter survival in malignant glioma. Plos One. 7: e41036. PMID 22829908 DOI: 10.1371/Journal.Pone.0041036  0.493
2012 Pellakuru LG, Iwata T, Gurel B, Schultz D, Hicks J, Bethel C, Yegnasubramanian S, De Marzo AM. Global levels of H3K27me3 track with differentiation in vivo and are deregulated by MYC in prostate cancer. The American Journal of Pathology. 181: 560-9. PMID 22713676 DOI: 10.1016/J.Ajpath.2012.04.021  0.608
2012 Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, Edwards J, Isaacs WB, Nelson PS, Bluemn E, Plymate SR, Luo J. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Research. 72: 3457-62. PMID 22710436 DOI: 10.1158/0008-5472.Can-11-3892  0.479
2012 Nelson WG, De Marzo AM, Yegnasubramanian S. USP2a activation of MYC in prostate cancer. Cancer Discovery. 2: 206-7. PMID 22585990 DOI: 10.1158/2159-8290.Cd-12-0027  0.694
2012 Easwaran H, Johnstone SE, Van Neste L, Ohm J, Mosbruger T, Wang Q, Aryee MJ, Joyce P, Ahuja N, Weisenberger D, Collisson E, Zhu J, Yegnasubramanian S, Matsui W, Baylin SB. A DNA hypermethylation module for the stem/progenitor cell signature of cancer. Genome Research. 22: 837-49. PMID 22391556 DOI: 10.1101/Gr.131169.111  0.433
2012 Uemura M, Zheng Q, Koh CM, Nelson WG, Yegnasubramanian S, Marzo AMD. Overexpression of ribosomal RNA in prostate cancer is common but not linked to rDNA promoter hypomethylation Oncogene. 31: 1254-1263. PMID 21822302 DOI: 10.1038/Onc.2011.319  0.739
2012 Sharad S, Li H, Haffner MC, Yegnasubramanian S, Petrovics G, Shiv S, Dobi A. Abstract B6: Epigenetic regulation of the androgen receptor regulator PMEPA1 in prostate cancer cells Cancer Research. 72: B6-B6. DOI: 10.1158/1538-7445.PRCA2012-B6  0.514
2012 Walker D, Haffner M, Deshpande N, Wyhs N, Marzo AD, Yegnasubramanian S, Nelson W. Abstract 992: Credentialing UHRF1 as a target for prostate cancer therapy Cancer Research. 72: 992-992. DOI: 10.1158/1538-7445.Am2012-992  0.729
2012 Huang W, Su LJ, Berndt SI, Moore LE, Katki HA, Yegnasubramanian S, Purdue MP. Abstract 51: Prospective study of LINE-1 hypomethylation in peripheral leukocyte DNA and colorectal cancer risk. Cancer Epidemiology Biomarkers & Prevention. 21: 51-51. DOI: 10.1158/1055-9965.Gwas-51  0.441
2012 Sharad S, Li H, Haffner M, Yegnasubramanian S, Petrovics G, Srivastava S, Dobi A. 967 Epigenetic Regulation Of The Androgen Receptor Regulator Pmepa1 In Prostate Cancer Cells The Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.1066  0.616
2012 Hedayati M, Zhang Y, Zhou H, Knight E, Wabler M, Haffner M, Yegnasubramanian S, DeWeese T. Exploiting Androgen-induced DNA Double-strand Breaks: Optimally Sequencing Androgen Suppression and Radiation for the Treatment of Prostate Cancer International Journal of Radiation Oncology*Biology*Physics. 84: S164. DOI: 10.1016/J.Ijrobp.2012.07.424  0.702
2011 Platz EA, Yegnasubramanian S, Liu JO, Chong CR, Shim JS, Kenfield SA, Stampfer MJ, Willett WC, Giovannucci E, Nelson WG. A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment. Cancer Discovery. 1: 68-77. PMID 22140654 DOI: 10.1158/2159-8274.Cd-10-0020  0.688
2011 Vaughn MP, Shinohara DB, Castagna N, Hicks JL, Netto G, de Marzo AM, Speed TJ, Reichert ZR, Kwabi-Addo B, Henderson CJ, Wolf CR, Yegnasubramanian S, Nelson WG. Humanizing π-class glutathione s-transferase regulation in a mouse model alters liver toxicity in response to acetaminophen overdose Plos One. 6. PMID 22022436 DOI: 10.1371/Journal.Pone.0025707  0.409
2011 Koh CM, Iwata T, Zheng Q, Bethel C, Yegnasubramanian S, De Marzo AM. Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget. 2: 669-83. PMID 21941025 DOI: 10.18632/Oncotarget.327  0.57
2011 Haffner MC, Chaux A, Meeker AK, Esopi DM, Gerber J, Pellakuru LG, Toubaji A, Argani P, Iacobuzio-Donahue C, Nelson WG, Netto GJ, De Marzo AM, Yegnasubramanian S. Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget. 2: 627-37. PMID 21896958 DOI: 10.18632/Oncotarget.316  0.675
2011 Nelson WG, Haffner MC, Yegnasubramanian S. Beefing up prostate cancer therapy with performance-enhancing (anti-) steroids. Cancer Cell. 20: 7-9. PMID 21741594 DOI: 10.1016/J.Ccr.2011.06.019  0.689
2011 Sfanos KS, Aloia AL, Hicks JL, Esopi DM, Steranka JP, Shao W, Sanchez-Martinez S, Yegnasubramanian S, Burns KH, Rein A, de Marzo AM. Identification of replication competent murine gammaretroviruses in commonly used prostate cancer cell lines Plos One. 6. PMID 21698104 DOI: 10.1371/Journal.Pone.0020874  0.525
2011 Yegnasubramanian S, Wu Z, Haffner MC, Esopi D, Aryee MJ, Badrinath R, He TL, Morgan JD, Carvalho B, Zheng Q, De Marzo AM, Irizarry RA, Nelson WG. Chromosome-wide mapping of DNA methylation patterns in normal and malignant prostate cells reveals pervasive methylation of gene-associated and conserved intergenic sequences. Bmc Genomics. 12: 313. PMID 21669002 DOI: 10.1186/1471-2164-12-313  0.606
2011 Koh CM, Gurel B, Sutcliffe S, Aryee MJ, Schultz D, Iwata T, Uemura M, Zeller KI, Anele U, Zheng Q, Hicks JL, Nelson WG, Dang CV, Yegnasubramanian S, De Marzo AM. Alterations in nucleolar structure and gene expression programs in prostatic neoplasia are driven by the MYC oncogene. The American Journal of Pathology. 178: 1824-34. PMID 21435462 DOI: 10.1016/J.Ajpath.2010.12.040  0.728
2011 Haffner MC, De Marzo AM, Meeker AK, Nelson WG, Yegnasubramanian S. Transcription-induced DNA double strand breaks: both oncogenic force and potential therapeutic target? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 3858-64. PMID 21385925 DOI: 10.1158/1078-0432.Ccr-10-2044  0.753
2011 Aryee MJ, Wu Z, Ladd-Acosta C, Herb B, Feinberg AP, Yegnasubramanian S, Irizarry RA. Accurate genome-scale percentage DNA methylation estimates from microarray data. Biostatistics (Oxford, England). 12: 197-210. PMID 20858772 DOI: 10.1093/Biostatistics/Kxq055  0.304
2011 Lin J, Haffner MC, Zhang Y, Lee BH, Brennen WN, Britton J, Kachhap SK, Shim JS, Liu JO, Nelson WG, Yegnasubramanian S, Carducci MA. Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth. The Prostate. 71: 333-43. PMID 20809552 DOI: 10.1002/Pros.21247  0.589
2011 Easwaran H, Johnstone SE, Neste LV, Ohm JE, Mosbruger T, Aryee M, Yegnasubramanian S, Matsui W, Baylin SB. Abstract LB-174: A DNA hypermethylation module for the stem/progenitor cell signature of cancer Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-174  0.467
2011 Huang W, Su JL, Hayes RB, Moore LE, Katki HA, Berndt SI, Weissfeld JL, Yegnasubramanian S, Purdue MP. Abstract 3755: Prospective study of genomic hypomethylation of leukocyte DNA and colorectal cancer risk Cancer Research. 71: 3755-3755. DOI: 10.1158/1538-7445.Am2011-3755  0.449
2011 Koh CM, Iwata T, Zheng Q, Bethel C, Yegnasubramanian S, Marzo AMD. Abstract 263: MYC enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and posttranscriptional mechanisms Cancer Research. 71: 263-263. DOI: 10.1158/1538-7445.Am2011-263  0.58
2011 Uemura M, Nelson WG, Yegnasubramanian S, Marzo AMD. Abstract 262: Complex epigenetic alterations induced by MYC during activation of the rDNA locus Cancer Research. 71: 262-262. DOI: 10.1158/1538-7445.Am2011-262  0.575
2010 Koh CM, Bieberich CJ, Dang CV, Nelson WG, Yegnasubramanian S, De Marzo AM. MYC and Prostate Cancer. Genes & Cancer. 1: 617-28. PMID 21779461 DOI: 10.1177/1947601910379132  0.731
2010 De Marzo AM, Nelson WG, Bieberich CJ, Yegnasubramanian S. Prostate cancer: New answers prompt new questions regarding cell of origin. Nature Reviews. Urology. 7: 650-2. PMID 21139640 DOI: 10.1038/Nrurol.2010.188  0.728
2010 Haffner MC, Aryee MJ, Toubaji A, Esopi DM, Albadine R, Gurel B, Isaacs WB, Bova GS, Liu W, Xu J, Meeker AK, Netto G, De Marzo AM, Nelson WG, Yegnasubramanian S. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nature Genetics. 42: 668-75. PMID 20601956 DOI: 10.1038/Ng.613  0.787
2010 Iwata T, Schultz D, Hicks J, Hubbard GK, Mutton LN, Lotan TL, Bethel C, Lotz MT, Yegnasubramanian S, Nelson WG, Dang CV, Xu M, Anele U, Koh CM, Bieberich CJ, et al. MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells. Plos One. 5: e9427. PMID 20195545 DOI: 10.1371/Journal.Pone.0009427  0.659
2010 Zhang P, Singh A, Yegnasubramanian S, Esopi D, Kombairaju P, Bodas M, Wu H, Bova SG, Biswal S. Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Molecular Cancer Therapeutics. 9: 336-46. PMID 20124447 DOI: 10.1158/1535-7163.Mct-09-0589  0.558
2010 Koh CM, Bieberich CJ, Dang CV, Nelson WG, Yegnasubramanian S, De Marzo AM. MYC and prostate cancer Genes and Cancer. 1: 617-628. DOI: 10.1177/1947601910379132  0.697
2010 Nelson WG, Haffner MC, Aryee MJ, Esopi DM, Isaacs WB, Bova GS, Meeker AK, Netto G, Marzo AMD, Yegnasubramanian S. Abstract CN05-04: Early molecular changes in prostate carcinogenesis Cancer Prevention Research. 3. DOI: 10.1158/1940-6207.Prev-10-Cn05-04  0.808
2010 Uemura M, Zheng Q, Nelson WG, Yegnasubramanian S, Marzo AMD. Abstract 175: Lack of rDNA promoter hypomethylation in clinical prostate cancer specimens and cell lines Cancer Research. 70: 175-175. DOI: 10.1158/1538-7445.Am10-175  0.726
2010 Kwabi-Addo B, Wang S, Yegnasubramanian S. Abstract B62: Epigenetic DNA methylation changes may underlie racial differences and susceptibility to prostate cancer. Cancer Epidemiology, Biomarkers & Prevention. 19. DOI: 10.1158/1055-9965.Disp-10-B62  0.627
2009 Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, Chowdhury WH, Kudrolli TA, Yegnasubramanian S, Luo J, Rodriguez R, Mendell JT, Lupold SE. miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Research. 69: 7165-9. PMID 19738047 DOI: 10.1158/0008-5472.Can-09-1448  0.382
2009 Bardia A, Platz EA, Yegnasubramanian S, De Marzo AM, Nelson WG. Anti-inflammatory drugs, antioxidants, and prostate cancer prevention. Current Opinion in Pharmacology. 9: 419-26. PMID 19574101 DOI: 10.1016/J.Coph.2009.06.002  0.7
2009 Nelson WG, De Marzo AM, Yegnasubramanian S. Epigenetic alterations in human prostate cancers. Endocrinology. 150: 3991-4002. PMID 19520778 DOI: 10.1210/En.2009-0573  0.733
2009 Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G, Chen L, Ewing CM, Eisenberger MA, Carducci MA, Nelson WG, Yegnasubramanian S, Luo J, Wang Y, Xu J, et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nature Medicine. 15: 559-65. PMID 19363497 DOI: 10.1038/Nm.1944  0.703
2009 Nelson WG, Marzo AMD, Yegnasubramanian S. Minireview: Epigenetic Alterations in Human Prostate Cancers Endocrinology. 150: 3991-4002. DOI: 10.1210/Edrv.30.5.9995  0.733
2009 Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G, Chen L, Ewing CM, Eisenberger MA, Carducci MA, Nelson WG, Yegnasubramanian S, Luo J, Wang Y, Xu J, et al. Erratum: Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer Nature Medicine. 15: 819-819. DOI: 10.1038/Nm0709-819A  0.721
2009 Iwata T, Schultz D, Vaughn M, Yegnasubramanian S, Nelson WG, Marzo AMD. Glutathione S-Transferase Pi (Gstp1) Deficiency Accelerates Prostate Carcinogenesis In The Lo-Myc Mouse The Journal of Urology. 181: 183-184. DOI: 10.1016/S0022-5347(09)60528-0  0.653
2008 Kim JW, Cheng Y, Liu W, Li T, Yegnasubramanian S, Zheng SL, Xu J, Isaacs WB, Chang BL. Genetic and epigenetic inactivation of LPL gene in human prostate cancer. International Journal of Cancer. 124: 734-8. PMID 19004026 DOI: 10.1002/Ijc.23972  0.617
2008 Yegnasubramanian S, Haffner MC, Zhang Y, Gurel B, Cornish TC, Wu Z, Irizarry RA, Morgan J, Hicks J, DeWeese TL, Isaacs WB, Bova GS, De Marzo AM, Nelson WG. DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Research. 68: 8954-67. PMID 18974140 DOI: 10.1158/0008-5472.Can-07-6088  0.81
2008 Gurel B, Iwata T, Koh CM, Yegnasubramanian S, Nelson WG, De Marzo AM. Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets Advances in Anatomic Pathology. 15: 319-331. PMID 18948763 DOI: 10.1097/Pap.0B013E31818A5C19  0.713
2008 Suzuki T, Farrar JE, Yegnasubramanian S, Zahed M, Suzuki N, Arceci RJ. Stable knockdown of PASG enhances DNA demethylation but does not accelerate cellular senescence in TIG-7 human fibroblasts. Epigenetics. 3: 281-91. PMID 18948754 DOI: 10.4161/Epi.3.5.6914  0.357
2008 Bastian PJ, Ellinger J, Von Rücker A, Müller SC, Yegnasubramanian S, Nelson WG, Stief CG. CpG island hypermethylation of the DNA: Perspectives of a molecular biomarker for prostate cancer | CpG-insel-hypermethylierung der DNA: Perspektiven eines molekularen biomarkers für das prostatakarzinom Urologe - Ausgabe A. 47: 1205-1207. PMID 18651120 DOI: 10.1007/S00120-008-1836-9  0.632
2008 Netto GJ, Nakai Y, Nakayama M, Jadallah S, Toubaji A, Nonomura N, Albadine R, Hicks JL, Epstein JI, Yegnasubramanian S, Nelson WG, De Marzo AM. Global DNA hypomethylation in intratubular germ cell neoplasia and seminoma, but not in nonseminomatous male germ cell tumors Modern Pathology. 21: 1337-1344. PMID 18622385 DOI: 10.1038/Modpathol.2008.127  0.511
2008 Nelson W, Haffner M, Speed T, Lee B, Yegnasubramanian S. Abstract CN01-01: Genetic and epigenetic changes in prostate cancer as targets for prevention Cancer Prevention Research. 1. DOI: 10.1158/1940-6207.Prev-08-Cn01-01  0.73
2008 Inoue H, Platz EA, Nakai Y, Fedor H, Nelson WG, Yegnasubramanian S, De Marzo AM. MAPPING OF DNA METHYLATION OF THE HUMAN GLUTATHIONE S-TRANSFERASE-π GENE (GSTP1) CpG ISLAND IN PRIMARY PROSTATE CANCER Journal of Urology. 179: 103-103. DOI: 10.1016/S0022-5347(08)60300-6  0.671
2007 Bastian PJ, Palapattu GS, Yegnasubramanian S, Rogers CG, Lin X, Mangold LA, Trock B, Eisenberger MA, Partin AW, Nelson WG. CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer. The Journal of Urology. 179: 529-535. PMID 18076941 DOI: 10.1016/J.Juro.2007.09.038  0.709
2007 Bastian PJ, Palapattu GS, Yegnasubramanian S, Lin X, Rogers CG, Mangold LA, Trock B, Eisenberger M, Partin AW, Nelson WG. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy Clinical Cancer Research. 13: 5361-5367. PMID 17875764 DOI: 10.1158/1078-0432.Ccr-06-2781  0.662
2007 Nelson WG, Yegnasubramanian S, Agoston AT, Bastian PJ, Lee BH, Nakayama M, De Marzo AM. Abnormal DNA methylation, epigenetics, and prostate cancer. Frontiers in Bioscience : a Journal and Virtual Library. 12: 4254-66. PMID 17485372 DOI: 10.2741/2385  0.703
2006 Yegnasubramanian S, Lin X, Haffner MC, DeMarzo AM, Nelson WG. Combination of methylated-DNA precipitation and methylation-sensitive restriction enzymes (COMPARE-MS) for the rapid, sensitive and quantitative detection of DNA methylation. Nucleic Acids Research. 34: e19. PMID 16473842 DOI: 10.1093/Nar/Gnj022  0.613
2006 Bastian PJ, Palapattu GS, Rogers CG, Lin X, Yegnasubramanian S, Mangold LA, Trock BJ, Eisenberger MA, Partin AW, Nelson WG. 849: Preoperative Serum Concentration of Cell-Free Circulating Cancer DNA in Patients with Prostate Cancer and the Risk of Recurrence after Radical Prostatectomy The Journal of Urology. 175: 274-274. DOI: 10.1016/S0022-5347(18)33085-4  0.694
2005 Lee BH, Yegnasubramanian S, Lin X, Nelson WG. Procainamide is a specific inhibitor of DNA methyltransferase 1. The Journal of Biological Chemistry. 280: 40749-56. PMID 16230360 DOI: 10.1074/Jbc.M505593200  0.596
2005 Bastian PJ, Palapattu GS, Lin X, Yegnasubramanian S, Mangold LA, Trock B, Eisenberger MA, Partin AW, Nelson WG. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clinical Cancer Research. 11: 4037-4043. PMID 15930338 DOI: 10.1158/1078-0432.Ccr-04-2446  0.715
2005 Agoston AT, Argani P, Yegnasubramanian S, De Marzo AM, Ansari-Lari MA, Hicks JL, Davidson NE, Nelson WG. Increased protein stability causes DNA methyltransferase 1 dysregulation in breast cancer Journal of Biological Chemistry. 280: 18302-18310. PMID 15755728 DOI: 10.1074/Jbc.M501675200  0.538
2005 Bastian PJ, Palapattu GS, Lin X, Yegnasubramanian S, Mangold LA, Trock BJ, Eisenberger MA, Partin AW, Nelson WG. 624Preoperative serum GSTP1 CPG island hypermethylation predicts the risk of early PSA recurrence following radical prostatectomy European Urology Supplements. 4: 158. DOI: 10.1016/S1569-9056(05)80628-1  0.484
2004 Bastian PJ, Yegnasubramanian S, Palapattu GS, Rogers CG, Lin X, De Marzo AM, Nelson WG. Molecular biomarker in prostate cancer: the role of CpG island hypermethylation. European Urology. 46: 698-708. PMID 15548435 DOI: 10.1016/J.Eururo.2004.07.022  0.726
2004 Gonzalgo ML, Yegnasubramanian S, Yan G, Rogers CG, Nicol TL, Nelson WG, Pavlovich CP. Molecular profiling and classification of sporadic renal cell carcinoma by quantitative methylation analysis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 7276-83. PMID 15534102 DOI: 10.1158/1078-0432.CCR-03-0692  0.427
2004 David GL, Yegnasubramanian S, Kumar A, Marchi VL, De Marzo AM, Lin X, Nelson WG. MDR1 promoter hypermethylation in MCF-7 human breast cancer cells: changes in chromatin structure induced by treatment with 5-Aza-cytidine. Cancer Biology & Therapy. 3: 540-8. PMID 15034303 DOI: 10.4161/Cbt.3.6.845  0.534
2004 Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, Bova GS, De Marzo AM, Isaacs WB, Nelson WG. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Research. 64: 1975-86. PMID 15026333 DOI: 10.1158/0008-5472.Can-03-3972  0.751
2004 Nakayama M, Gonzalgo ML, Yegnasubramanian S, Lin X, De Marzo AM, Nelson WG. GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. Journal of Cellular Biochemistry. 91: 540-52. PMID 14755684 DOI: 10.1002/Jcb.10740  0.736
Show low-probability matches.